PCAT6 may be a new prognostic biomarker in various cancers: a meta-analysis and bioinformatics analysis

Shi, Song-bo; Cheng, Qinghao; Gong, Sheng; Lu, Tingting; Guo, Shifang; Song, Shaoming; Yang, Yuping; Cui, Qi; Yang, Kehu; Qian, Yaowen

doi:10.1186/s12935-021-02079-4

Cited by 7 publications

(6 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, prostate cancer-associated transcript 6 (PCAT6) was significantly increased in various cancers. The overexpression of PCAT6 was closely correlated with OS, TNM stage, distant metastasis, LNM, tumor size, and the degree of differentiation in cancer patients ( Shi et al, 2021 ), which may be a new cancer-related biomarker. In recent years, numerous studies found that the HOXA-AS2 was overexpressed in a variety of tumor types, such as CC ( Chen and He, 2021 ), OSCC ( Chen et al, 2021 ), PCa ( Xiao and Song, 2020 ) and so on.…”

Section: Discussionmentioning

confidence: 97%

HOXA-AS2 may be a potential prognostic biomarker in human cancers: A meta-analysis and bioinformatics analysis

Zhang

Zhang²,

Zhang³

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Background: Dysregulation of long non-coding (lncRNA) has been reported in various solid tumors. HOXA cluster antisense RNA 2 (HOXA-AS2) is a newly identified lncRNA with abnormal expression in several human malignancies. However, its prognostic value remains controversial. This meta-analysis synthesized available data to clarify the association between HOXA-AS2 expression levels and clinical prognosis in multiple cancers.Methods: Four public databases (Embase, PubMed, Web of Science, The Cochrane Library) were used to identify eligible studies. Hazard ratios (HRs) and odds ratios (ORs) with their 95% confidence intervals (CIs) were combined to assess the correlation of HOXA-AS2 expression with survival outcomes and clinicopathological features of cancer patients. Publication bias was measured using Begg’s funnel plot and Egger’s regression test, and the stability of the combined results was measured using sensitivity analysis. Additionally, multiple public databases were screened and extracted to validate the results of this meta-analysis.Results: The study included 20 studies, containing 1331 patients. The meta-analysis showed that the overexpression of HOXA-AS2 was associated with poor overall survival (HR = 2.06, 95% CI 1.58–2.69, p < 0.001). In addition, the high expression of HOXA-AS2 could forecast advanced tumor stage (OR = 3.89, 95% CI 2.90–5.21, p < 0.001), earlier lymph node metastasis (OR = 3.48, 95% CI 2.29–5.29, p < 0.001), larger tumor size (OR = 2.36, 95% CI 1.52–3.66, p < 0.001) and earlier distant metastasis (OR = 3.54, 95% CI 2.00–6.28, p < 0.001). However, other clinicopathological features, including age (OR = 1.09, 95% CI 0.86–1.38, p = 0.467), gender (OR = 0.92, 95% CI 0.72–1.18, p = 0.496), depth of invasion (OR = 2.13, 95% CI 0.77–5.90, p = 0.146) and differentiation (OR = 1.02, 95% CI 0.65–1.59, p = 0.945) were not significantly different from HOXA-AS2 expression.Conclusion: Our study showed that the overexpression of HOXA-AS2 was related to poor overall survival and clinicopathological features. HOXA-AS2 may serve as a potential prognostic indicator and therapeutic target for tumor treatment.

show abstract

Section: Discussionmentioning

confidence: 97%

HOXA-AS2 may be a potential prognostic biomarker in human cancers: A meta-analysis and bioinformatics analysis

Zhang

Zhang²,

Zhang³

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…Despite being an inert tumor that possesses a high overall survival (OS) rate, PCa progresses rapidly after the turning point of recurrence, even with the available clinical interventions (8). Thus, consistent with other PCa prognostic studies (38)(39)(40)(41)(42), DFS was selected as the endpoint of this study.…”

Section: Discussionmentioning

confidence: 98%

A combined signature of glycolysis and immune landscape predicts prognosis and therapeutic response in prostate cancer

Guo

Wang²,

Yan³

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

Prostate cancer (PCa) is a common malignancy that poses a major threat to the health of men. Prostate-specific antigen (PSA) and its derivatives, as FDA-approved detection assays, are insufficient to serve as optimal markers for patient prognosis and clinical decision-making. It is widely acknowledged that aberrant glycolytic metabolism in PCa is related to tumor progression and acidifies the tumor microenvironment (TME). Considering the non-negligible impacts of glycolysis and immune functions on PCa, we developed a combined classifier in prostate cancer. The Glycolysis Score containing 19 genes and TME Score including three immune cells were created, using the univariate and multivariate Cox proportional hazards model, log-rank test, least absolute shrinkage and selection operator (LASSO) regression analysis and the bootstrap approach. Combining the glycolysis and immunological landscape, the Glycolysis-TME Classifier was then constructed. It was observed that the classifier was more accurate in predicting the prognosis of patients than the current biomarkers. Notably, there were significant differences in metabolic activity, signaling pathways, mutational landscape, immunotherapeutic response, and drug sensitivity among the Glycolysishigh/TMElow, Mixed group and Glycolysislow/TMEhigh identified by this classifier. Overall, due to the significant prognostic value and potential therapeutic guidance of the Glycolysis-TME Classifier, we anticipate that this classifier will be clinically beneficial in the management of patients with PCa.

show abstract

“…LncRNA CRNDE was identified as an oncogenic lncRNA and involved in tumor growth and metastasis ( 21 - 23 ). A growing body of research has shown PCAT6 playing key roles in many different cancers, with the upregulation of this lncRNA being associated with worse prognostic outcomes and clinical features, underscoring its promising utility as a prognostic biomarker ( 24 ). For example, one study of osteosarcoma samples revealed higher PCAT6 expression in these tumors relative to paracancerous normal bone tissue, with such upregulation being linked to worse patient survival and a more malignant phenotype ( 25 ).…”

Section: Discussionmentioning

confidence: 99%

LncRNA PCAT6 is a predictor of poor prognosis of colorectal cancer

Han,

Li,

Zhang

et al. 2024

J Gastrointest Oncol

View full text Add to dashboard Cite

Background The long non-coding RNA (lncRNA) prostate cancer-associated transcript 6 (PCAT6) has been studied in many cancers, yet its relationship with colorectal cancer (CRC) remains poorly defined. Here, we conducted an analysis of The Cancer Genome Atlas (TCGA) database to better clarify the role of PCAT6 in this cancer type. Methods Wilcoxon rank-sum tests were utilized to assess relative levels of PCAT6 in CRC tumors and normal tissues, while logistic regression analyses were utilized to compare the relationships between PCAT6 levels and clinicopathological findings. Kaplan-Meier curves and Cox regression analyses were used to gauge correlations between PCAT6 and patient survival outcomes, while the biological roles of this lncRNA were investigated via a gene set enrichment analysis (GSEA) approach. The expression level of PCAT6 in CRC cell lines was detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Results PCAT6 levels were significantly correlated with CRC patient lymph node metastasis (N) stage [odds ratio (OR) =1.8 for N1 & N2 vs. N0], lymphatic invasion [OR =1.9 for yes vs. no), distant metastasis (M stage) (OR =2.1 for M1 vs. M0), carcinoembryonic antigen (CEA) level (OR =1.9 for >5 vs. ≤5), perineural invasion (OR =1.9 for yes vs. no), pathologic stage (OR =1.9 for stage III/IV vs. stage I/II), and neoplasm type (OR =2.1 for rectal adenocarcinoma vs. colon adenocarcinoma) (all P<0.05). CRC patients expressing higher PCAT6 levels exhibited poorer survival outcomes than those expressing low levels of this lncRNA (P=0.017), and in univariate analyses, higher PCAT6 levels were linked to worse overall survival [hazard ratio (HR) =1.540; 95% confidence interval (CI): 1.079–2.199; P=0.017], with this relationship also being preserved in a multivariate analysis (HR =6.892; 95% CI: 1.713–27.727, P=0.007). GSEA revealed high PCAT6 expression to be linked to differential DNA methylation enrichment, with high PCAT6 levels being associated with changes in base excision repair, cellular senescence, G2/M DNA damage checkpoint, chromatin-modifying enzyme, and gene silencing by RNA activity. The high expression of lncRNA PCAT6 in CRC cell lines was demonstrated by PCR experiments. Conclusions PCAT6 represents a promising prognostic biomarker of poor CRC patient survival outcomes, with DNA methylation and RNA-mediated gene silencing being potentially promising mechanistic pathways whereby this lncRNA may shape patient outcomes.

show abstract

PCAT6 may be a new prognostic biomarker in various cancers: a meta-analysis and bioinformatics analysis

Cited by 7 publications

References 43 publications

HOXA-AS2 may be a potential prognostic biomarker in human cancers: A meta-analysis and bioinformatics analysis

HOXA-AS2 may be a potential prognostic biomarker in human cancers: A meta-analysis and bioinformatics analysis

A combined signature of glycolysis and immune landscape predicts prognosis and therapeutic response in prostate cancer

LncRNA PCAT6 is a predictor of poor prognosis of colorectal cancer

Contact Info

Product

Resources

About